Following the paradigm of other common BC biomarkers (i.e. ER, PR, HER2, PD-L1), little is known about how PIK3CA mutational status would change during metastatic progression and potentially drive treatment selection in BC patients. The gene discussed is ERBB2; the disease is breast cancer.